SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS
Serum concentration of osteocalcin (OC) was measured in sera from untreated patients with Graves' disease, hypothyroidism due to Hashimoto's thyroiditis, and subacute thyroiditis. Serum concentration of OC in Graves' disease and hypothyroidism were 14.1+/-5.6-mu-g/L and 3.8+/-2.7-mu-g...
Gespeichert in:
| Veröffentlicht in: | Journal of endocrinological investigation 1992-07, Vol.15 (7), p.491-496 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 496 |
|---|---|
| container_issue | 7 |
| container_start_page | 491 |
| container_title | Journal of endocrinological investigation |
| container_volume | 15 |
| creator | KOJIMA, N SAKATA, S NAKAMURA, S NAGAI, K TAKUNO, H OGAWA, T MATSUI SARUI, H MIURA, K |
| description | Serum concentration of osteocalcin (OC) was measured in sera from untreated patients with Graves' disease, hypothyroidism due to Hashimoto's thyroiditis, and subacute thyroiditis. Serum concentration of OC in Graves' disease and hypothyroidism were 14.1+/-5.6-mu-g/L and 3.8+/-2.7-mu-g/L, respectively which were significantly different from that of healthy subjects (Graves' disease, p |
| doi_str_mv | 10.1007/BF03348786 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_A1992JL87700002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73347766</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-a756e02f1206acff2bd01fab77d4dddfc06d01991d540e72819b4bfdf1a7beab3</originalsourceid><addsrcrecordid>eNqNkMFr2zAUxsXoyNJsl90LOpQd2nmTLMdPPrqus7gkdogdSk9GliXwSOzOcij976uQrLlWPBD6vt974n0IfafkFyUEft_NCGMeB-5_QmMKLnE44_4FGhMWUMcjAXxBl8b8JYQB4zBCI-p5YBvGaJfH680SR1kaxWmxDoskS3OczXCWF3EWhYsoSbGtlXUskOPHpJjj-dMqXhfzp3WW3Cf58udByM5vHKb3ON_chdGmiPF_vUjyr-izFlujvp3uCdrM4iKaO4vsT2I_cySjdHAETH1FXE1d4guptVvVhGpRAdReXddaEt8KQUDrqUcUuJwGlVfpWlMBlRIVm6Afx7nPffdvr8xQ7hoj1XYrWtXtTQk2LgDft-DNEZR9Z0yvdPncNzvRv5aUlIdsy3O2Fr46Td1XO1Wf0WOY1r8--cJIsdW9aGVj3jGP8SljrsVuj9iLqjptZKNaqd6p0O7lPiw4ALHnQPOP01EziKHp2qjbtwN7A_Afmck</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73347766</pqid></control><display><type>article</type><title>SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS</title><source>Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>MEDLINE</source><source>SpringerNature Journals</source><creator>KOJIMA, N ; SAKATA, S ; NAKAMURA, S ; NAGAI, K ; TAKUNO, H ; OGAWA, T ; MATSUI ; SARUI, H ; MIURA, K</creator><creatorcontrib>KOJIMA, N ; SAKATA, S ; NAKAMURA, S ; NAGAI, K ; TAKUNO, H ; OGAWA, T ; MATSUI ; SARUI, H ; MIURA, K</creatorcontrib><description>Serum concentration of osteocalcin (OC) was measured in sera from untreated patients with Graves' disease, hypothyroidism due to Hashimoto's thyroiditis, and subacute thyroiditis. Serum concentration of OC in Graves' disease and hypothyroidism were 14.1+/-5.6-mu-g/L and 3.8+/-2.7-mu-g/L, respectively which were significantly different from that of healthy subjects (Graves' disease, p<0.001, hypothyroidism, p<0.01). Serum concentration of OC in patients with subacute thyroiditis was 8.0+/-3.5-mu-g/L which was not statistically different from age-matched normal controls. Serial measurement of serum OC for 24 mo in 15 patients with Graves' disease after initiation of antithyroid drugs disclosed that the decline of serum OC was obtained only 24 mo after antithyroid drug therapy. On the other hand, in hypothyroid patients, increased serum OC was observed after 1-2 months treatment of L-T4. Correlation coefficients between serum concentrations of OC and T3, T4, FT3 or FT4 in all the patients with thyroid disorders were 0.66, 0.51, 0.50 and 0.54, respectively, which were statistically significant (all, p<0.001). These results suggest that osteoblastic activity is enhanced in hyperthyroidism and suppressed in hypothyroidism. In hyperthyroid patients, despite of normalization of FT4 concentration in relatively short period (within 3-4 mo), it took 24 mo after initiation of antithyroid drugs for OC to normalize, suggesting not only thyroid hormone per se but also some unknown factor(s) participates in serum OC secretion. In contrast to thyrotoxic patients, rapid increase in serum OC after initiation of supplemental L-T4 treatment in hypothyroidism was observed, suggesting a direct effect of thyroid hormone on the osteoblasts in patients with hypothyroidism.</description><identifier>ISSN: 0391-4097</identifier><identifier>EISSN: 1720-8386</identifier><identifier>DOI: 10.1007/BF03348786</identifier><identifier>PMID: 1447487</identifier><identifier>CODEN: JEIND7</identifier><language>eng</language><publisher>MILANO: Editrice Kurtis S R L</publisher><subject>Adult ; Alkaline Phosphatase - blood ; Biological and medical sciences ; Endocrinology & Metabolism ; Endocrinopathies ; Female ; Graves Disease - blood ; Graves Disease - drug therapy ; Humans ; Hypothyroidism - blood ; Hypothyroidism - drug therapy ; Hypothyroidism - etiology ; Life Sciences & Biomedicine ; Male ; Medical sciences ; Methimazole - therapeutic use ; Middle Aged ; Non tumoral diseases. Target tissue resistance. Benign neoplasms ; Osteocalcin - blood ; Propylthiouracil - therapeutic use ; Regression Analysis ; Science & Technology ; Thyroid. Thyroid axis (diseases) ; Thyroiditis, Autoimmune - complications ; Thyroiditis, Subacute - blood ; Thyrotropin - blood ; Thyroxine - blood ; Thyroxine - therapeutic use ; Triiodothyronine - blood</subject><ispartof>Journal of endocrinological investigation, 1992-07, Vol.15 (7), p.491-496</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>16</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wosA1992JL87700002</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c311t-a756e02f1206acff2bd01fab77d4dddfc06d01991d540e72819b4bfdf1a7beab3</citedby><cites>FETCH-LOGICAL-c311t-a756e02f1206acff2bd01fab77d4dddfc06d01991d540e72819b4bfdf1a7beab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27197,27929,27930</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4385332$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1447487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOJIMA, N</creatorcontrib><creatorcontrib>SAKATA, S</creatorcontrib><creatorcontrib>NAKAMURA, S</creatorcontrib><creatorcontrib>NAGAI, K</creatorcontrib><creatorcontrib>TAKUNO, H</creatorcontrib><creatorcontrib>OGAWA, T</creatorcontrib><creatorcontrib>MATSUI</creatorcontrib><creatorcontrib>SARUI, H</creatorcontrib><creatorcontrib>MIURA, K</creatorcontrib><title>SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS</title><title>Journal of endocrinological investigation</title><addtitle>J ENDOCRINOL INVEST</addtitle><addtitle>J Endocrinol Invest</addtitle><description>Serum concentration of osteocalcin (OC) was measured in sera from untreated patients with Graves' disease, hypothyroidism due to Hashimoto's thyroiditis, and subacute thyroiditis. Serum concentration of OC in Graves' disease and hypothyroidism were 14.1+/-5.6-mu-g/L and 3.8+/-2.7-mu-g/L, respectively which were significantly different from that of healthy subjects (Graves' disease, p<0.001, hypothyroidism, p<0.01). Serum concentration of OC in patients with subacute thyroiditis was 8.0+/-3.5-mu-g/L which was not statistically different from age-matched normal controls. Serial measurement of serum OC for 24 mo in 15 patients with Graves' disease after initiation of antithyroid drugs disclosed that the decline of serum OC was obtained only 24 mo after antithyroid drug therapy. On the other hand, in hypothyroid patients, increased serum OC was observed after 1-2 months treatment of L-T4. Correlation coefficients between serum concentrations of OC and T3, T4, FT3 or FT4 in all the patients with thyroid disorders were 0.66, 0.51, 0.50 and 0.54, respectively, which were statistically significant (all, p<0.001). These results suggest that osteoblastic activity is enhanced in hyperthyroidism and suppressed in hypothyroidism. In hyperthyroid patients, despite of normalization of FT4 concentration in relatively short period (within 3-4 mo), it took 24 mo after initiation of antithyroid drugs for OC to normalize, suggesting not only thyroid hormone per se but also some unknown factor(s) participates in serum OC secretion. In contrast to thyrotoxic patients, rapid increase in serum OC after initiation of supplemental L-T4 treatment in hypothyroidism was observed, suggesting a direct effect of thyroid hormone on the osteoblasts in patients with hypothyroidism.</description><subject>Adult</subject><subject>Alkaline Phosphatase - blood</subject><subject>Biological and medical sciences</subject><subject>Endocrinology & Metabolism</subject><subject>Endocrinopathies</subject><subject>Female</subject><subject>Graves Disease - blood</subject><subject>Graves Disease - drug therapy</subject><subject>Humans</subject><subject>Hypothyroidism - blood</subject><subject>Hypothyroidism - drug therapy</subject><subject>Hypothyroidism - etiology</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Methimazole - therapeutic use</subject><subject>Middle Aged</subject><subject>Non tumoral diseases. Target tissue resistance. Benign neoplasms</subject><subject>Osteocalcin - blood</subject><subject>Propylthiouracil - therapeutic use</subject><subject>Regression Analysis</subject><subject>Science & Technology</subject><subject>Thyroid. Thyroid axis (diseases)</subject><subject>Thyroiditis, Autoimmune - complications</subject><subject>Thyroiditis, Subacute - blood</subject><subject>Thyrotropin - blood</subject><subject>Thyroxine - blood</subject><subject>Thyroxine - therapeutic use</subject><subject>Triiodothyronine - blood</subject><issn>0391-4097</issn><issn>1720-8386</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EZCTM</sourceid><sourceid>EIF</sourceid><recordid>eNqNkMFr2zAUxsXoyNJsl90LOpQd2nmTLMdPPrqus7gkdogdSk9GliXwSOzOcij976uQrLlWPBD6vt974n0IfafkFyUEft_NCGMeB-5_QmMKLnE44_4FGhMWUMcjAXxBl8b8JYQB4zBCI-p5YBvGaJfH680SR1kaxWmxDoskS3OczXCWF3EWhYsoSbGtlXUskOPHpJjj-dMqXhfzp3WW3Cf58udByM5vHKb3ON_chdGmiPF_vUjyr-izFlujvp3uCdrM4iKaO4vsT2I_cySjdHAETH1FXE1d4guptVvVhGpRAdReXddaEt8KQUDrqUcUuJwGlVfpWlMBlRIVm6Afx7nPffdvr8xQ7hoj1XYrWtXtTQk2LgDft-DNEZR9Z0yvdPncNzvRv5aUlIdsy3O2Fr46Td1XO1Wf0WOY1r8--cJIsdW9aGVj3jGP8SljrsVuj9iLqjptZKNaqd6p0O7lPiw4ALHnQPOP01EziKHp2qjbtwN7A_Afmck</recordid><startdate>19920701</startdate><enddate>19920701</enddate><creator>KOJIMA, N</creator><creator>SAKATA, S</creator><creator>NAKAMURA, S</creator><creator>NAGAI, K</creator><creator>TAKUNO, H</creator><creator>OGAWA, T</creator><creator>MATSUI</creator><creator>SARUI, H</creator><creator>MIURA, K</creator><general>Editrice Kurtis S R L</general><general>Kurtis</general><scope>BLEPL</scope><scope>DTL</scope><scope>EZCTM</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920701</creationdate><title>SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS</title><author>KOJIMA, N ; SAKATA, S ; NAKAMURA, S ; NAGAI, K ; TAKUNO, H ; OGAWA, T ; MATSUI ; SARUI, H ; MIURA, K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-a756e02f1206acff2bd01fab77d4dddfc06d01991d540e72819b4bfdf1a7beab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Adult</topic><topic>Alkaline Phosphatase - blood</topic><topic>Biological and medical sciences</topic><topic>Endocrinology & Metabolism</topic><topic>Endocrinopathies</topic><topic>Female</topic><topic>Graves Disease - blood</topic><topic>Graves Disease - drug therapy</topic><topic>Humans</topic><topic>Hypothyroidism - blood</topic><topic>Hypothyroidism - drug therapy</topic><topic>Hypothyroidism - etiology</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Methimazole - therapeutic use</topic><topic>Middle Aged</topic><topic>Non tumoral diseases. Target tissue resistance. Benign neoplasms</topic><topic>Osteocalcin - blood</topic><topic>Propylthiouracil - therapeutic use</topic><topic>Regression Analysis</topic><topic>Science & Technology</topic><topic>Thyroid. Thyroid axis (diseases)</topic><topic>Thyroiditis, Autoimmune - complications</topic><topic>Thyroiditis, Subacute - blood</topic><topic>Thyrotropin - blood</topic><topic>Thyroxine - blood</topic><topic>Thyroxine - therapeutic use</topic><topic>Triiodothyronine - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOJIMA, N</creatorcontrib><creatorcontrib>SAKATA, S</creatorcontrib><creatorcontrib>NAKAMURA, S</creatorcontrib><creatorcontrib>NAGAI, K</creatorcontrib><creatorcontrib>TAKUNO, H</creatorcontrib><creatorcontrib>OGAWA, T</creatorcontrib><creatorcontrib>MATSUI</creatorcontrib><creatorcontrib>SARUI, H</creatorcontrib><creatorcontrib>MIURA, K</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 1992</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of endocrinological investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOJIMA, N</au><au>SAKATA, S</au><au>NAKAMURA, S</au><au>NAGAI, K</au><au>TAKUNO, H</au><au>OGAWA, T</au><au>MATSUI</au><au>SARUI, H</au><au>MIURA, K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS</atitle><jtitle>Journal of endocrinological investigation</jtitle><stitle>J ENDOCRINOL INVEST</stitle><addtitle>J Endocrinol Invest</addtitle><date>1992-07-01</date><risdate>1992</risdate><volume>15</volume><issue>7</issue><spage>491</spage><epage>496</epage><pages>491-496</pages><issn>0391-4097</issn><eissn>1720-8386</eissn><coden>JEIND7</coden><abstract>Serum concentration of osteocalcin (OC) was measured in sera from untreated patients with Graves' disease, hypothyroidism due to Hashimoto's thyroiditis, and subacute thyroiditis. Serum concentration of OC in Graves' disease and hypothyroidism were 14.1+/-5.6-mu-g/L and 3.8+/-2.7-mu-g/L, respectively which were significantly different from that of healthy subjects (Graves' disease, p<0.001, hypothyroidism, p<0.01). Serum concentration of OC in patients with subacute thyroiditis was 8.0+/-3.5-mu-g/L which was not statistically different from age-matched normal controls. Serial measurement of serum OC for 24 mo in 15 patients with Graves' disease after initiation of antithyroid drugs disclosed that the decline of serum OC was obtained only 24 mo after antithyroid drug therapy. On the other hand, in hypothyroid patients, increased serum OC was observed after 1-2 months treatment of L-T4. Correlation coefficients between serum concentrations of OC and T3, T4, FT3 or FT4 in all the patients with thyroid disorders were 0.66, 0.51, 0.50 and 0.54, respectively, which were statistically significant (all, p<0.001). These results suggest that osteoblastic activity is enhanced in hyperthyroidism and suppressed in hypothyroidism. In hyperthyroid patients, despite of normalization of FT4 concentration in relatively short period (within 3-4 mo), it took 24 mo after initiation of antithyroid drugs for OC to normalize, suggesting not only thyroid hormone per se but also some unknown factor(s) participates in serum OC secretion. In contrast to thyrotoxic patients, rapid increase in serum OC after initiation of supplemental L-T4 treatment in hypothyroidism was observed, suggesting a direct effect of thyroid hormone on the osteoblasts in patients with hypothyroidism.</abstract><cop>MILANO</cop><pub>Editrice Kurtis S R L</pub><pmid>1447487</pmid><doi>10.1007/BF03348786</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0391-4097 |
| ispartof | Journal of endocrinological investigation, 1992-07, Vol.15 (7), p.491-496 |
| issn | 0391-4097 1720-8386 |
| language | eng |
| recordid | cdi_webofscience_primary_A1992JL87700002 |
| source | Web of Science - Science Citation Index Expanded - 1992<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; MEDLINE; SpringerNature Journals |
| subjects | Adult Alkaline Phosphatase - blood Biological and medical sciences Endocrinology & Metabolism Endocrinopathies Female Graves Disease - blood Graves Disease - drug therapy Humans Hypothyroidism - blood Hypothyroidism - drug therapy Hypothyroidism - etiology Life Sciences & Biomedicine Male Medical sciences Methimazole - therapeutic use Middle Aged Non tumoral diseases. Target tissue resistance. Benign neoplasms Osteocalcin - blood Propylthiouracil - therapeutic use Regression Analysis Science & Technology Thyroid. Thyroid axis (diseases) Thyroiditis, Autoimmune - complications Thyroiditis, Subacute - blood Thyrotropin - blood Thyroxine - blood Thyroxine - therapeutic use Triiodothyronine - blood |
| title | SERUM CONCENTRATIONS OF OSTEOCALCIN IN PATIENTS WITH HYPERTHYROIDISM, HYPOTHYROIDISM AND SUBACUTE THYROIDITIS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-16T01%3A58%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SERUM%20CONCENTRATIONS%20OF%20OSTEOCALCIN%20IN%20PATIENTS%20WITH%20HYPERTHYROIDISM,%20HYPOTHYROIDISM%20AND%20SUBACUTE%20THYROIDITIS&rft.jtitle=Journal%20of%20endocrinological%20investigation&rft.au=KOJIMA,%20N&rft.date=1992-07-01&rft.volume=15&rft.issue=7&rft.spage=491&rft.epage=496&rft.pages=491-496&rft.issn=0391-4097&rft.eissn=1720-8386&rft.coden=JEIND7&rft_id=info:doi/10.1007/BF03348786&rft_dat=%3Cproquest_webof%3E73347766%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73347766&rft_id=info:pmid/1447487&rfr_iscdi=true |